Abstract. Utilizing the human genome database, the recently developed G-protein-coupled receptors (GPCRs) deorphanizing strategy successfully identified multiple receptors of free fatty acids (FFAs). FFAs have been demonstrated to act as ligands of several GPCRs (FFAR1, FFAR2, FFAR3, and GPR120). These fatty acid receptors are proposed to play critical roles in various types of physiological homeostases. FFAR1 and GPR120 are activated by medium-and long-chain FFAs. In contrast, FFAR2 and FFAR3 are activated by short-chain FFAs.
Introduction
Free fatty acids (FFAs) are not only essential nutrients but they also contribute to many cellular functions. Nuclear receptors, including peroxisome proliferatoractivated receptors (PPARs), work as 'sensors' of FFA. They maintain homeostasis under physiological and pathophysiological conditions by coordinating the expression of proteins involved in lipid uptake, synthesis, transport, storage, degradation, and elimination (1) . However, these mechanisms could not explain all biological effects of FFAs. Some effects appear to occur independently of PPARs and rather to involve cell-surface receptors (2, 3) . Recently, the G-protein-coupled receptor (GPCR) deorphanizing strategy (4) has successfully identified multiple receptors for FFAs, which function on the cell surface and play significant roles in nutrition regulation (Table 1 ). FFAR2 and FFAR3 are activated by short-chain FFAs, whereas FFAR1 and GPR120 can be activated by medium-and long-chain FFAs. Many groups have reported that all four of these free fatty acid receptors (FFARs) are expressed in the gastrointestinal tract and that they play several important roles in the signal transduction of FFAs. This review gives an update on recent advances in our understanding of the FFA sensing in the gastrointestinal tract via these FFARs.
FFAR1 (GPR40)

Ligands
FFAR1, FFAR2, and FFAR3 were identified and found to be located in tandem on human chromosome 19q13. The members of this subfamily share approximately 30% -40% identity. FFAR1 is activated by medium-and long-chain saturated and unsaturated FFAs (5 -7); on the other hand, FFAR2 and FFAR3 are both activated by short-chain FFAs (8 -10) . A variety of fatty acids were found to act as agonists of FFAR1 in the micromolar concentration range, with eicosatrienoic acid being the most potent (5). Interestingly, whereas the potency of the saturated fatty acids was dependent on chain length, with pentadecanoic acid (C15) and palmitic acid (C16) being the most potent, among the unsaturated fatty acids, potency did not appear to correlate with carbon chain length or degree of saturation (5) .
Due to its biological activity and tissue distribution, FFAR1 is an attractive drug target for type 2 diabetes, and its potential in this regard has been investigated. A selective FFAR1 antagonist, GW1100, which reverses the effects of GW9508, has been described (11) . The antidiabetic thiazolidinediones troglitazone and rosiglitazone and the experimental anti-obesity compound MEDICA16 also activate FFAR1 (10) . Recently, we reported that a flow cytometry-based binding assay could successfully identify direct interactions between FFAR1 and its ligands, GW9508 and MEDICA16 (12) . As a result, these compounds are expected to be useful in the further investigation of FFAR1, and this approach would be of value in studying the pharmacology of GPCRs.
Physiological function in the intestine
FFAR1 is expressed in β-cells where it contributes to FFA enhancement of glucose-stimulated insulin secretion. However, other sites of FFAR1 expression, including the intestine, have been suggested (6, 13) . By the analysis of mice in which the FFAR1-coding sequence had been replaced with that of β-galactosidase, Edfalk et al. revealed that FFAR1 protein is expressed in the endocrine cells of the gastrointestinal tract, including cells that express the incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), and mediates FFA-stimulated incretin secretion. Furthermore, FFAR1-null mice show impaired secretion of both GIP and GLP-1 in response to acute, oral fat diet administration with a concomitant reduction in insulin secretion and glucose clearance. Together, these findings provide evidence for a role for FFAR1 in FFA stimulation of incretin secretion (14) . These reports suggest that FFAR1 modulates FFA-stimulated insulin secretion from β-cells not only directly but also indirectly.
Physiological function in the other tissues
Expression analysis of FFAR1 by reverse transcription-polymerase chain reaction (RT-PCR), immunohistochemistry, and in situ hybridization revealed high levels of expression in insulin-producing pancreatic islet cells (6). Itoh et al. revealed that long-chain FFAs amplify glucose-stimulated insulin secretion from pancreatic β-cells by activating FFAR1 (6) . FFAR1-deficient β-cells secrete less insulin in response to FFAs, and loss of FFAR1 protects mice from obesity-induced hyperinsulinemia, hepatic steatosis, hypertriglyceridemia, increased hepatic glucose output, hyperglycemia, and glucose intolerance. Conversely, overexpression of FFAR1 in β-cells under the control of the mouse Ipf1/Pdx1 promoter leads to impaired β-cell function, hyperinsulinemia, and diabetes (13) . In addition, the overexpression of FFAR1 under the control of the mouse insulin II promoter demonstrated that FFAR1 regulates glucose-stimulated insulin secretion (15) . These reports suggest that FFAR1 plays an important role in the mechanisms that link obesity and type 2 diabetes.
FFAR2 (GPR43) and FFAR3 (GPR41)
Ligands
FFAR2 and FFAR3 are both activated by short-chain FFAs such as formate, acetate, propionate, butyrate, and pentanonate (8 -10) . FFAR2 and FFAR3 differ in their specificity for ligands with different lengths of carbon chain. FFAR3 is activated equally by propionate, butyrate, and pentanonate, whereas FFAR2 prefers propionate to the other short-chain FFAs (8, 9).
Physiological function in the intestine
FFAR2 has been shown to be present in a variety of tissues, being particularly evident in fat stores, and the gastrointestinal tract. Karaki et al. reported that FFAR2 is expressed in enteroendocrine cells that are expressing PYY and mucosal mast cells that contain 5-hydroxytryptamine (5-HT) (16) . This is consistent with physiological data showing that short-chain FFAs stimulate the release of peptide YY (PYY) (17) and 5-HT (18) from the ileum and colon.
The analysis of FFAR3-deficient mice showed that (20, 21) . Furthermore, adipocytes treated with acetate and propionate exhibit a reduction in lipolytic activity. This inhibition of lipolysis is the result of activation of FFAR2 because the effect is abolished in adipocytes from FFAR2-knockout animals. Activation of FFAR2 by acetate results in a reduction in the plasma level of FFAs (21) . This result is consistent with that of a previous in vitro experiment, which showed that activation of FFAR2 results in the reduction of lipolysis and activation of adipogenesis. These results suggest a potential role for FFAR2 in regulating plasma lipid profiles and perhaps aspects of metabolic syndrome (20) . Further studies are needed to clarify the differences between these results.
FFAR3 is expressed abundantly in adipose tissue (8) and has been implicated in the leptin production by the stimulation of short-chain FFAs in adipocytes (22) . The mouse adipocyte cell line Ob-Luc produces leptin upon stimulation with short-chain FFAs. The leptin production is increased by the overexpression of exogenous FFAR3 and abolished by the knockdown of FFAR3 expression with siRNA (22) . Acute oral administration of propionate increases circulating leptin levels in mice, which suggests that the effects of propionate are mediated via FFAR3 in vivo. Given that leptin is a potent anorexigenic hormone that acts via its receptors in the central nervous system to reduce food intake (23), propionate may inhibit food intake by increasing leptin release.
GPR120
Ligands
We identified medium-to long-chain FFAs as the endogenous ligands of GPR120 using a receptor internalization assay (24) . Apparent stimulatory activities were detected for saturated FFAs with a carbon chain length of 14 to 18 and for unsaturated FFAs with a chain length of 16 to 22. Despite their similarity in ligand specificity, human GPR120 shares only 10% amino acid identity with FFAR1, which is on a distant branch of the evolutionary tree. Therefore, the similarity in ligand specificity might be the result of convergent evolution.
The pharmacology of FFAR1 and GPR120
is not yet fully understood because of the lack of selective ligands for GPR120. Recently, we have succeeded in the synthesis of GPR120-selective agonist (25) and in identifying the gliforin derivatives as selective natural GPR120 partial agonists (26) . These results provide a basis for the construction of new tools to probe the biology of GPR120 and for the development of new candidates for therapeutic agents.
Physiological function in the intestine
GPR120 is highly expressed in the human and mouse intestinal tract and mouse enteroendocrine STC-1 cells. We showed previously that GLP-1-expressing endocrine cells in the large intestine express GPR120 (27, 28) (Fig.  1) . The FFA-mediated secretion of GLP-1 and cholecystokinin (CCK) and the increase in intracellular Ca can be inhibited by siRNA that targets GPR120 but not FFAR1 (29) . It was also noted that oral administration, or local application to the colon, of FFAs (27) increased circulating GLP-1 and insulin levels in mice, and it is tempting to speculate that the effects of the FFAs are mediated via GPR120 and FFAR1 in vivo. As GPR120 and FFAR1 are activated by similar properties of FFAs, both GPR120 and FFAR1 will be important for assessing the mechanism of FFA-mediated insulin secretion and for the treatment of diabetes.
Physiological function in other tissues
GPR120 is expressed not only in the intestine, but also in a number of other tissues, including adipocytes and taste buds. GPR120 might play a physiological role in these tissues, but at present, the functional consequences of GPR120 activation in these tissues remains unclear.
Gotoh et al. showed that GPR120 is also highly expressed in human and mouse adipose tissue. The expression of GPR120 mRNA is higher in adipocytes than in stromal-vascular cells, and in addition, it increases during adipocyte differentiation of 3T3-L1 cells. Moreover the use of an siRNA to down-regulate GPR120 expression resulted in the inhibition of adipocyte differentiation (30) . These results indicated that GPR120 has an important role in adipogenesis as a factor that facilitates the maturation of adipocytes. However, the precise molecular mechanism by which GPR120 functions in adipocytes is unclear. Further studies of the relationship between obesity and GPR120 should be of considerable interest.
Matsumura et al. detected GPR120 mRNA and immunoreactivity in rat taste buds (31) . Furthermore, double immunostaining for GPR120 and markers of type II taste cells (phospholipase-Cβ2 and α-gustducin) revealed that the majority of GPR120-positive taste cells are type II cells (32) . The expression of GPR120 in type II taste cells suggests that the receptor might function as a sensor for dietary fat, in a similar manner to its function in enteroendocrine cells.
Conclusion
FFAR1, FFAR2, FFAR3, and GPR120 have been identified as a group of FFARs, and all of these FFARs are expressed in the gastrointestinal tract. These receptors play significant roles in nutritional regulation by sensing several classes of FFAs as follows: FFAR1 and GPR120 mediate the secretion of long chain FFAstimulated incretin, such as GLP-1 (6, 27) ; on the other hand, FFAR2 and FFAR3 control the release of PYY by short-chain FFAs (17 -19) .
As we have briefly reviewed the role of the FFARs, it has been clarified that the physiological and pharmacological functions of these FFARs are in the gastrointestinal tract. However, to elucidate the physiological functions of these nutrient-sensing receptors in more detail, it is essential to detect and analyze not only the mRNA for the receptors but also the protein product. Utilizing specific antibodies and knockout mice, we identified novel tissue distributions of the FFAR1 and GPR120 proteins (27, 28, 33) . In addition, we and other groups discovered selective ligands for these FFARs (7, 11, 25, 26) . Further studies using specific antibodies, knockout mice, and selective agonists might reveal novel physiological roles of these FFARs in energy homeostasis. Furthermore, the direct binding of FFAs to FFARs must be detected to analyze the pharmacological functions of these receptors. The FFARs bind with lower affinity (in the micromolar or millimolar range) than that of the classical high-affinity ligands, such as hormones or growth factors, for their receptors (34) . Due to the low binding affinity of FFAs (in the micromolar range) and nonspecific binding to other fatty acid-binding proteins, it is difficult to show the direct binding of FFAs to FFARs. However, we have successfully developed a flow cytometry-based assay that can be used to detect the direct binding of FFAs to FFARs (12) . Our approach should be useful for studying other GPCRs that have a low affinity for their ligands. The physiological and pharmacological functional analysis of these FFARs should be valuable for understanding nutrient metabolism and might lead to the discovery of novel therapies and drugs for metabolic diseases. 
